Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways.
Capricor’s lead candidate, CAP-1002, is an “off-the-shelf” cardiac cell therapy that is currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials.
Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. We are focused on developing a precision-engineered exosome platform technology that has the ability to deliver defined sets of effector molecules that exert their effects through defined mechanisms of action. Capricor is developing its exosome technologies as a next generation platform in a variety of diseases.